{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:16:54Z","timestamp":1786979814880,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,10,9]],"date-time":"2012-10-09T00:00:00Z","timestamp":1349740800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s00223-012-9646-x","type":"journal-article","created":{"date-parts":[[2012,10,8]],"date-time":"2012-10-08T02:43:11Z","timestamp":1349664191000},"page":"387-394","source":"Crossref","is-referenced-by-count":12,"title":["COX-2-Selective NSAIDs and Risk of Hip or Knee Replacements: A Population-Based Case\u2013Control Study"],"prefix":"10.1007","volume":"91","author":[{"given":"Corinne","family":"Klop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arief","family":"Lalmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon C.","family":"Mastbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert G. M.","family":"Leufkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willemijn H.","family":"Noort-van der Laan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes W. J.","family":"Bijlsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paco M. J.","family":"Welsing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,9]]},"reference":[{"key":"9646_CR1","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(11)60243-2","volume":"377","author":"JWJ Bijlsma","year":"2011","unstructured":"Bijlsma JWJ, Berenbaum F, Lafeber FPJG (2011) Osteoarthritis: an update with relevance for clinical practice. Lancet 377:2115\u20132126","journal-title":"Lancet"},{"key":"9646_CR2","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.joca.2010.01.013","volume":"18","author":"W Zhang","year":"2010","unstructured":"Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK et al (2010) OARSI recommendations for the management of hip and knee osteoarthritis: part III. Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 18:476\u2013499","journal-title":"Osteoarthritis Cartilage"},{"key":"9646_CR3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/rheumatology\/kei171","volume":"45","author":"G Verbruggen","year":"2006","unstructured":"Verbruggen G (2006) Chondroprotective drugs in degenerative joint diseases. Rheumatology 45:129\u2013138","journal-title":"Rheumatology"},{"key":"9646_CR4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/ar3437","volume":"13","author":"MC Zweers","year":"2011","unstructured":"Zweers MC, de Boer TN, van Roon JAG, Bijlsma JWJ, Lafeber FPJG, Mastbergen SC (2011) Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis. Arthritis Res Ther 13:239","journal-title":"Arthritis Res Ther"},{"key":"9646_CR5","first-page":"2444","volume":"30","author":"H Hajjaji El","year":"2003","unstructured":"El Hajjaji H, Marcelis A, Devogelaer JP, Manicourt DH (2003) Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. J Rheumatol 30:2444\u20132451","journal-title":"J Rheumatol"},{"key":"9646_CR6","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.joca.2005.02.004","volume":"13","author":"SC Mastbergen","year":"2005","unstructured":"Mastbergen SC, Bijlsma JW, Lafeber FP (2005) Selective COX-2 inhibition is favorable to human early and late stage osteoarthritic cartilage: a human in vitro study. Osteoarthritis Cartilage 13:519\u2013526","journal-title":"Osteoarthritis Cartilage"},{"key":"9646_CR7","doi-asserted-by":"crossref","first-page":"R2","DOI":"10.1186\/ar1846","volume":"8","author":"SC Mastbergen","year":"2006","unstructured":"Mastbergen SC, Jansen NW, Bijlsma JW, Lafeber FP (2006) Differential direct effects of cyclo-oxygenase-1\/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study. Arthritis Res Ther 8:R2","journal-title":"Arthritis Res Ther"},{"key":"9646_CR8","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/sj.bjp.0703710","volume":"131","author":"L Blot","year":"2000","unstructured":"Blot L, Marcelis A, Devogelaer JP, Manicourt DH (2000) Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br J Pharmacol 131:1413\u20131421","journal-title":"Br J Pharmacol"},{"key":"9646_CR9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/rheumatology\/kei187","volume":"45","author":"SC Mastbergen","year":"2006","unstructured":"Mastbergen SC, Marijnissen AC, Vianen ME, Zoer B, Roermund PM, Bijlsma JW, Lafeber FP (2006) Inhibition of COX-2 by celecoxib in the canine groove model of osteoarthritis. Rheumatology 45:405\u2013413","journal-title":"Rheumatology"},{"key":"9646_CR10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/art.33324","volume":"64","author":"A Fukai","year":"2012","unstructured":"Fukai A, Kamekura S, Chikazu D, Nakagawa T, Hirata M, Saito T et al (2012) Lack of chondroprotective effect of cyclooxygenase-2 inhibition in a mouse surgical osteoarthritis model. Arthritis Rheum 64:198\u2013203","journal-title":"Arthritis Rheum"},{"key":"9646_CR11","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.joca.2008.09.002","volume":"17","author":"TN Boer de","year":"2009","unstructured":"de Boer TN, Huisman AM, Polak AA, Niehoff AG, van Rinsum AC, Saris D et al (2009) The chondroprotective effect of selective COX-2 inhibition in osteoarthritis: ex vivo evaluation of human cartilage tissue after in vivo treatment. Osteoarthritis Cartilage 17:482\u2013488","journal-title":"Osteoarthritis Cartilage"},{"issue":"Suppl 2","key":"9646_CR12","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1016\/S1063-4584(10)60355-X","volume":"18","author":"TN Boer de","year":"2010","unstructured":"de Boer TN, Mastbergen SC, Huisman AM, Polak AA, Bijlsma JW, Lafeber FP (2010) Lack of disease modifying activity of celecoxib in end-stage OA: a randomized controlled trial. Osteoarthritis Cartilage 18(Suppl 2):S145","journal-title":"Osteoarthritis Cartilage"},{"key":"9646_CR13","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0149-2918(02)80096-0","volume":"24","author":"EA Tindall","year":"2002","unstructured":"Tindall EA, Sharp JT, Burr A, Katz TK, Wallemark CB, Verburg K et al (2002) A 12-month, multicenter, prospective, open-label trial of radiographic analysis of disease progression in osteoarthritis of the knee or hip in patients receiving celecoxib. Clin Ther 24:2051\u20132063","journal-title":"Clin Ther"},{"key":"9646_CR14","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1002\/art.23973","volume":"58","author":"AD Sawitzke","year":"2008","unstructured":"Sawitzke AD, Shi H, Finco MF, Dunlop DD, Bingham CO 3rd, Harris CL et al (2008) The effect of glucosamine and\/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine\/chondroitin arthritis intervention trial. Arthritis Rheum 58:3183\u20133191","journal-title":"Arthritis Rheum"},{"key":"9646_CR15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.semarthrit.2009.10.003","volume":"40","author":"JP Raynauld","year":"2010","unstructured":"Raynauld JP, Martel-Pelletier J, Beaulieu A, Bessette L, Morin F, Choquette D et al (2010) An open-label pilot study evaluating by magnetic resonance imaging the potential for a disease-modifying effect of celecoxib compared to a modelized historical control cohort in the treatment of knee osteoarthritis. Semin Arthritis Rheum 40:185\u2013192","journal-title":"Semin Arthritis Rheum"},{"key":"9646_CR16","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.amjmed.2009.03.022","volume":"122","author":"C Ding","year":"2009","unstructured":"Ding C, Cicuttini F, Jones G (2009) Do NSAIDs affect longitudinal changes in knee cartilage volume and knee cartilage defects in older adults? Am J Med 122:836\u2013842","journal-title":"Am J Med"},{"key":"9646_CR17","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1002\/art.21357","volume":"52","author":"M Reijman","year":"2005","unstructured":"Reijman M, Bierma-Zeinstra SM, Pols HA, Koes BW, Stricker BH, Hazes JM (2005) Is there an association between the use of different types of nonsteroidal anti-inflammatory drugs and radiologic progression of osteoarthritis? The Rotterdam Study. Arthritis Rheum 52:3137\u20133142","journal-title":"Arthritis Rheum"},{"key":"9646_CR18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(89)90651-X","volume":"2","author":"S Rashad","year":"1989","unstructured":"Rashad S, Revell P, Hemingway A, Low F, Rainsford K, Walker F (1989) Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet 2:519\u2013522","journal-title":"Lancet"},{"key":"9646_CR19","doi-asserted-by":"crossref","unstructured":"Herings RMC (2007) The PHARMO System. CNS Spectr 12:9 Suppl 16:14\u201317. http:\/\/www.primarypsychiatry.com\/aspx\/articledetail.aspx?articleid=1826 . Accessed on 6 Aug 2012","DOI":"10.1017\/S1092852900026262"},{"key":"9646_CR20","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/HJH.0b013e3282f0ab4a","volume":"26","author":"F Vries de","year":"2008","unstructured":"de Vries F, Pouwels S, Bracke M, Lammers JW, Leufkens H, Klungel O et al (2008) Use of inhaled corticosteroids and the risk of non-fatal acute myocardial infarction. J Hypertens 26:124\u2013129","journal-title":"J Hypertens"},{"key":"9646_CR21","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1007\/s00198-010-1455-3","volume":"22","author":"ME Arbouw","year":"2011","unstructured":"Arbouw ME, Movig KL, van Staa TP, Egberts AC, Souverein PC, de Vries F (2011) Dopaminergic drugs and the risk of hip or femur fracture: a population-based case-control study. Osteoporos Int 22:2197\u20132204","journal-title":"Osteoporos Int"},{"key":"9646_CR22","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2125.2007.03077.x","volume":"65","author":"F Vries de","year":"2008","unstructured":"de Vries F, Pouwels S, Bracke M, Lammers JW, Klungel O, Leufkens H et al (2008) Use of beta2 agonists and risk of acute myocardial infarction in patients with hypertension. Br J Clin Pharmacol 65:580\u2013586","journal-title":"Br J Clin Pharmacol"},{"key":"9646_CR23","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1210\/jc.2009-2342","volume":"95","author":"S Pouwels","year":"2010","unstructured":"Pouwels S, Lalmohamed A, van Staa T, Cooper C, Souverein P, Leufkens HG et al (2010) Use of organic nitrates and the risk of hip fracture: a population-based case-control study. J Clin Endocrinol Metab 95:1924\u20131931","journal-title":"J Clin Endocrinol Metab"},{"key":"9646_CR24","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00198-010-1337-8","volume":"22","author":"S Pouwels","year":"2011","unstructured":"Pouwels S, Lalmohamed A, Souverein P, Cooper C, Veldt BJ, Leufkens HG et al (2011) Use of proton pump inhibitors and risk of hip\/femur fracture: a population-based case-control study. Osteoporos Int 22:903\u2013910","journal-title":"Osteoporos Int"},{"key":"9646_CR25","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00198-009-0849-6","volume":"20","author":"MW Brand van den","year":"2009","unstructured":"van den Brand MW, Pouwels S, Samson MM, van Staa TP, Thio B, Cooper C et al (2009) Use of anti-depressants and the risk of fracture of the hip or femur. Osteoporos Int 20:1705\u20131713","journal-title":"Osteoporos Int"},{"key":"9646_CR26","unstructured":"SAS\/STAT 9.2 user\u2019s guide, 2nd ed. Example 64.5 Conditional logistic regression for m:n matching. http:\/\/support.sas.com\/documentation\/cdl\/en\/statug\/63033\/HTML\/default\/viewer.htm#statug_phreg_sect036.htm . Accessed on 9 Aug 2012"},{"key":"9646_CR27","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/00001648-199507000-00005","volume":"6","author":"S Greenland","year":"1995","unstructured":"Greenland S (1995) Dose\u2013response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 6:356\u2013365","journal-title":"Epidemiology"},{"key":"9646_CR28","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1161\/STROKEAHA.109.554055","volume":"40","author":"S Pouwels","year":"2009","unstructured":"Pouwels S, Lalmohamed A, Leufkens B, de Boer A, Cooper C, van Staa T et al (2009) Risk of hip\/femur fracture after stroke: a population-based case-control study. Stroke 40:3281\u20133285","journal-title":"Stroke"},{"key":"9646_CR29","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1302\/0301-620X.93B7.25737","volume":"93","author":"O Rolfson","year":"2011","unstructured":"Rolfson O, K\u00e4rrholm J, Dahlberg LE, Garellick G (2011) Patient-reported outcomes in the Swedish Hip Arthroplasty Register\u2014results of a nationwide prospective observational study. J Bone Joint Surg Br 93:867\u2013875","journal-title":"J Bone Joint Surg Br"},{"key":"9646_CR30","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.joca.2011.02.018","volume":"19","author":"PG Conaghan","year":"2011","unstructured":"Conaghan PG, Hunter DJ, Maillefert JF, Reichmann WM, Losina E (2011) Summary and recommendations of the OARSI FDA Osteoarthritis Assessment of Structural Change Working Group. Osteoarthritis Cartilage 19:606\u2013610","journal-title":"Osteoarthritis Cartilage"},{"key":"9646_CR31","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/ard.2005.046920","volume":"65","author":"MA Alvarez-Soria","year":"2006","unstructured":"Alvarez-Soria MA, Largo R, Santillana J, Sanchez-Pernaute O, Colvo E, Hernandez M et al (2006) Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac. Ann Rheum Dis 65:998\u20131005","journal-title":"Ann Rheum Dis"},{"key":"9646_CR32","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.joca.2008.04.022","volume":"16","author":"MA Alvarez-Soria","year":"2008","unstructured":"Alvarez-Soria MA, Herrero-Beaumont G, Moreno-Rubio J, Calvo E, Santillana J, Egido J et al (2008) Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis. Osteoarthritis Cartilage 16:1484\u20131493","journal-title":"Osteoarthritis Cartilage"},{"key":"9646_CR33","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/art.10356","volume":"46","author":"MM Hardy","year":"2002","unstructured":"Hardy MM, Seibert K, Manning PT, Currie MG, Woerner BM, Edwards D et al (2002) Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum 46:1789\u20131803","journal-title":"Arthritis Rheum"},{"key":"9646_CR34","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/sim.4780100409","volume":"10","author":"H Petri","year":"1991","unstructured":"Petri H, Urquhart J (1991) Channeling bias in the interpretation of drug effects. Stat Med 10:577\u2013581","journal-title":"Stat Med"},{"key":"9646_CR35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/oxfordjournals.rheumatology.a005738","volume":"42","author":"TM MacDonald","year":"2003","unstructured":"MacDonald TM, Pettitt D, Lee FH, Schwartz JS (2003) Channelling of patients taking NSAIDs or cyclooxygenase-2-specific inhibitors and its effect on interpretation of outcomes. Rheumatology 42:3\u201310","journal-title":"Rheumatology"},{"key":"9646_CR36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/pds.909","volume":"13","author":"SZ Zhao","year":"2004","unstructured":"Zhao SZ, Wentworth C, Burke TA, Makuch RW (2004) Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. Pharmacoepidemiol Drug Saf 13:277\u2013287","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"9646_CR37","first-page":"618","volume":"139","author":"E Schee van der","year":"2004","unstructured":"van der Schee E, van Dijk L, Blom L, Lelie-van der Zande R, Broerse A (2004) Medicatiebewaking rond recept\u2014en zelfzorggeneesmiddelen. Consumentenpanel Gezondheidszorg peilt leemtes. Pharm Weekbl 139:618\u2013622","journal-title":"Pharm Weekbl"},{"key":"9646_CR38","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.2106\/JBJS.I.00882","volume":"92","author":"AB Pedersen","year":"2010","unstructured":"Pedersen AB, Sorensen HT, Mehnert F, Overgaard S, Johnsen SP (2010) Risk factors for venous thromboembolism in patients undergoing total hip replacement and receiving routine thromboprophylaxis. J Bone Joint Surg Am 92:2156\u20132164","journal-title":"J Bone Joint Surg Am"},{"key":"9646_CR39","unstructured":"National Joint Registry for England and Wales (2011) NJR 8th annual report. www.njrcentre.org.uk . Accessed on 25 July 2012"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-012-9646-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-012-9646-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-012-9646-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T07:41:04Z","timestamp":1558683664000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-012-9646-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,9]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["9646"],"URL":"https:\/\/doi.org\/10.1007\/s00223-012-9646-x","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,9]]}}}